Cibinqo is the brand name for abrocitinib, an oral JAK1 inhibitor made by Pfizer. The FDA approved Cibinqo in January 2022 for adults and adolescents 12 years and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when those therapies are inadvisable. Cibinqo comes in 50mg, 100mg, and 200mg tablets taken once daily. The drug carries an FDA boxed warning covering serious infections, malignancy, major cardiovascular events, thrombosis, and death, the same class-wide warning applied to other JAK inhibitors such as Rinvoq (upadacitinib).
Pfizer's wholesale list price for Cibinqo runs close to $6,500 per month in 2026, and cash prices at retail pharmacies range from $5,691 to $7,128 depending on the pharmacy and dose. What a patient actually pays depends heavily on insurance type: commercially insured patients typically pay $0 to a few hundred dollars per month using Pfizer's copay savings card, while Medicare and Medicaid patients rely on plan formulary tiers and the 2026 Part D annual out-of-pocket cap. Patients weighing Cibinqo against other eczema treatments should also compare Dupixent, a biologic injection, and Rinvoq, a competing JAK1 inhibitor, since prior authorization criteria and step therapy rules often push patients between all three.
Prior authorization is required by nearly every commercial insurer, Medicare Part D plan, and state Medicaid program before covering Cibinqo. Most plans require documented failure of at least one topical corticosteroid or calcineurin inhibitor, and many require a documented trial of a biologic such as Dupixent before approving a JAK inhibitor, given the boxed warning. Because Cibinqo has no J-code and is never billed as an infused or injected drug, it is a Medicare Part D drug rather than a Part B drug, and there is no ASP-based reimbursement rate published by CMS for it. Patients researching the Medicaid income limits in their state should confirm whether their state's preferred drug list favors Cibinqo, Rinvoq, or a biologic first.
What Cibinqo Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same cibinqo can cost many times more at a hospital than at your local pharmacy:
2026 Cibinqo Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $5,691 - $7,128/month | Cash price for a 30-day supply without insurance or a manufacturer coupon, 2026 GoodRx and SingleCare data |
| Medicare Part D (2026) | $100 - $700/month, capped at $2,100/year | Covered on the specialty formulary tier of most Part D plans; prior authorization required; no drug-specific cap beyond the general 2026 Part D annual out-of-pocket cap |
| Commercial insurance | $0 - $700/month before copay card, $0 after | Prior authorization and documented topical or biologic failure are standard; the Pfizer copay savings card reduces most commercially insured patients to $0 per fill |
| Pfizer Cibinqo Copay Savings Card | $0/month (up to $15,000/year, max 13 fills) | Commercial insurance only; not usable by patients with Medicare, Medicaid, TRICARE, or VA coverage under federal anti-kickback law |
| Medicaid | $1 - $4/prescription, with PA | Coverage and step-therapy requirements vary by state; many state preferred drug lists require documented biologic failure before Cibinqo approval |
Retail prices reflect 2026 GoodRx and SingleCare survey data. Part D and commercial ranges depend on your plan's specialty formulary tier and where you are in your benefit year. Medicaid figures reflect typical nominal copay ranges; actual coverage varies significantly by state.
Source: CMS Part D 2026 benefit design, Pfizer patient support programs, GoodRx, SingleCare
Why Hospitals Charge So Much
Cibinqo is almost always dispensed as a self-administered oral tablet through a retail or specialty pharmacy, so it rarely appears on a hospital bill. When it does show up on an inpatient or hospital outpatient bill, usually because a patient's home supply ran out during a stay or a hospital pharmacy dispensed a bridge supply, the facility markup can push the charge well above the retail cash price. Hospital chargemaster rates typically add pharmacy handling fees, dispensing fees, and administrative overhead on top of the drug's acquisition cost, which can bring a 30-day-equivalent charge to $8,500 to $14,000.
Pfizer's wholesale acquisition cost for a 30-tablet supply runs close to $6,500 in 2026. Charges on an itemized hospital bill significantly above that figure are often facility markups that can be disputed. Because Cibinqo has no permanent HCPCS J-code and is not administered by infusion or injection, Medicare Part B reimbursement essentially does not apply to it; the drug is billed through Part D pharmacy channels instead. If a hospital bill lists Cibinqo at an inflated rate, request an itemized statement and the National Drug Code to compare against the wholesale acquisition cost.
Patient Assistance Programs
Pfizer runs two separate programs for Cibinqo: a commercial copay savings card and a Pfizer Patient Assistance Program for uninsured or underinsured patients, including Medicare beneficiaries. These follow different eligibility rules. IMPORTANT: Federal anti-kickback statute (42 U.S.C. Section 1320a-7b) prohibits manufacturer copay cards from being used by patients covered by Medicare, Medicaid, TRICARE, or VA. However, the separate Pfizer Patient Assistance Program can provide free Cibinqo directly to Medicare Part D and Medicare Advantage patients who meet the income threshold, because it is a charitable free-drug program rather than a cost-sharing subsidy.
Patient assistance programs for Cibinqo| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Cibinqo Copay Savings Card (commercially insured patients only) | $0/month for most commercially insured patients; up to $15,000 per calendar year, maximum 13 fills; not available to Medicare, Medicaid, TRICARE, or VA patients | cibinqo.com |
| Pfizer Patient Assistance Program (uninsured, underinsured, and Medicare-eligible) | Free Cibinqo for patients with household income at or below approximately 300% FPL ($47,880 for a household of 1 in 2026); uniquely open to Medicare Part D and Medicare Advantage patients who qualify | pfizerrxpathways.com |
| Pfizer Dermatology Patient Access (coverage-delay bridge program) | Free Cibinqo for up to 2 years, shipped through Interim Care Rx, for commercially insured patients facing a coverage delay, denial, or prior authorization gap | pfizerdermatologypatientaccess.com |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies; a fallback option for patients who do not qualify for Pfizer programs | needymeds.org |
The Cibinqo Copay Savings Card is not available to patients whose primary insurance is Medicare, Medicaid, TRICARE, or VA under federal anti-kickback law. Unlike some manufacturer patient assistance programs that require Medicare patients to apply for Part D Extra Help first, Pfizer's Cibinqo Patient Assistance Program directly evaluates Medicare Part D and Medicare Advantage patients against the 300% FPL income threshold. Call 1-833-956-3376 or visit cibinqo.com to confirm current program terms and eligibility.
Source: cibinqo.com, pfizerrxpathways.com, pfizerdermatologypatientaccess.com, NeedyMeds.org
Medicare Part D
Cibinqo is covered as a specialty formulary tier drug by most Medicare Part D and Medicare Advantage prescription drug plans in 2026. Prior authorization is standard, typically requiring documentation of failed topical therapy and, for many plans, a documented biologic trial given Cibinqo's boxed warning. Once a Medicare patient's out-of-pocket spending on all Part D covered drugs reaches $2,100 in a calendar year, the 2026 annual out-of-pocket cap applies and the patient pays $0 for the remainder of the year.
Pfizer's Cibinqo Copay Savings Card does not work with Medicare Part D or Medicare Advantage. Federal anti-kickback rules prohibit manufacturers from subsidizing cost sharing for government-insured patients through commercial coupons. Instead, Medicare beneficiaries should apply directly to the Pfizer Patient Assistance Program, which uniquely evaluates Medicare Part D and Medicare Advantage patients against a 300% FPL income threshold for free drug, and can also apply for Part D Extra Help (Low Income Subsidy) through the Social Security Administration at 1-800-772-1213 to reduce cost sharing on other Part D drugs.
Cibinqo was not among the 10 drugs selected for the first round of Medicare's Inflation Reduction Act drug price negotiation, and it is not on the announced second or third round lists. As a result, there is no negotiated Maximum Fair Price for Cibinqo in 2026. The Inflation Reduction Act's negotiation program prioritizes high-Medicare-spend drugs that have been on the market for at least seven years (small molecules) or eleven years (biologics); Cibinqo, approved in January 2022, remains too new and too low-volume relative to other Part D drugs to have been selected. Medicare patients pay under standard Part D rules including the $2,100 annual cap rather than a negotiated price.
Common Cibinqo Billing Errors
If you got a bill for Cibinqo above $700 with commercial insurance, or your Medicare Part D cost share seems inflated, check for these issues before paying:
- Prior authorization not submitted or denied without a documented appeal. Nearly every plan requires PA for Cibinqo given its cost and boxed warning; if your dermatologist's office did not submit one, you may be paying cash unnecessarily.
- Wrong dose strength billed. Cibinqo comes in 50mg, 100mg, and 200mg tablets at different per-tablet prices; confirm the National Drug Code on your bill matches the strength your prescriber actually prescribed.
- Pfizer copay savings card not applied at the pharmacy counter even though you have qualifying commercial insurance. Ask the pharmacist to rerun the claim with the copay card BIN and PCN before paying full cost share.
- 90-day mail-order supply billed as three separate monthly copays instead of one 90-day copay tier, which some Part D and commercial plans offer at a discount.
- Charged the deductible or coinsurance rate after you already reached the $2,100 Part D annual out-of-pocket cap for the calendar year.
- Pharmacist substitutes a different JAK inhibitor (such as Rinvoq) without prescriber approval, since these are not interchangeable drugs even though they share a drug class and boxed warning language.
Frequently Asked Questions
How much does Cibinqo cost without insurance in 2026?
The cash retail price for Cibinqo in 2026 ranges from $5,691 to $7,128 for a 30-day supply of 100mg or 200mg tablets, depending on the pharmacy, with a GoodRx-reported average around $6,498. Discount cards like SingleCare can shave a few hundred dollars off that price, but the biggest savings come from Pfizer's copay savings card for commercially insured patients or the Pfizer Patient Assistance Program for uninsured patients earning at or below 300% of the Federal Poverty Level, which can supply the drug free.
Is there a generic version of Cibinqo?
No. Abrocitinib, sold as Cibinqo, has no FDA-approved generic as of 2026. The drug's 5-year New Chemical Entity exclusivity allows Paragraph IV patent challenges starting January 14, 2026 (four years post-approval), though full exclusivity runs through January 14, 2027, and three active US patents are expected to block generic entry until approximately 2034, and possibly as late as 2036 if patent litigation delays occur. Because abrocitinib is a small-molecule drug rather than a biologic, any future lower-cost version would be a generic through the FDA's ANDA pathway, not a biosimilar.
How do I apply for the Pfizer Patient Assistance Program for Cibinqo?
Call 1-833-956-3376 or visit pfizerrxpathways.com to start. You will need a completed enrollment form signed by both you and your prescriber, proof of household income (tax return or pay stubs), proof of US residency, a valid Cibinqo prescription, and documentation of your insurance status. Household income must be at or below approximately 300% of the Federal Poverty Level, which is $47,880 for a single-person household in 2026. Processing typically takes 10 to 15 business days, and approved patients receive free Cibinqo shipped to their home or prescriber's office.
Can I use the Cibinqo copay savings card with Medicare?
No. Federal anti-kickback law bars manufacturer copay savings cards from being used by anyone on Medicare, Medicaid, TRICARE, or VA benefits. The Cibinqo Copay Savings Card is for commercially insured patients only and can reduce cost to $0 per month up to $15,000 per year. Medicare patients should instead apply to the Pfizer Patient Assistance Program, which directly evaluates Medicare Part D and Medicare Advantage patients against a 300% FPL income threshold for free drug.
What if my insurance denies coverage for Cibinqo?
Request a written denial notice, then file a formal appeal within 60 days with a prescriber letter documenting your atopic dermatitis diagnosis and prior treatment failures. Ask your prescriber to request a peer-to-peer review with the plan's medical director. If step therapy is the issue, your prescriber can file a step-therapy exception citing contraindications or documented prior failures. If all appeals fail, apply to the Pfizer Patient Assistance Program or, for commercially insured patients, ask about Pfizer Dermatology Patient Access, which can supply free Cibinqo for up to 2 years during a coverage gap.
Does the IRA negotiated price apply to Cibinqo?
No. Cibinqo was not selected for any round of Medicare's Inflation Reduction Act drug price negotiation program, so there is no negotiated Maximum Fair Price for it in 2026. Approved in January 2022, Cibinqo has not yet reached the minimum market tenure the negotiation program requires. Medicare patients pay under standard 2026 Part D rules, including the $2,100 annual out-of-pocket cap that applies across all their covered Part D drugs combined.
Do I qualify for the Pfizer Patient Assistance Program for Cibinqo?
You may qualify if your household income is at or below approximately 300% of the Federal Poverty Level, which is $47,880 for one person, $64,920 for two people, or $99,000 for a family of four in 2026. You must be a US resident with a valid Cibinqo prescription and be uninsured, underinsured, or covered by Medicare Part D or Medicare Advantage. Commercially insured patients above the income threshold should instead use the Cibinqo Copay Savings Card, which has no income requirement.
How is Cibinqo different from Dupixent and Rinvoq for eczema?
Cibinqo (abrocitinib) and Rinvoq (upadacitinib) are both oral JAK1 inhibitors that carry the same FDA boxed warning for serious infections, cardiovascular events, and cancer risk. Dupixent (dupilumab) is an injectable biologic with no boxed warning and a different mechanism, blocking IL-4 and IL-13 signaling rather than JAK1. Many insurers require patients to try Dupixent or a topical therapy before approving Cibinqo or Rinvoq because of the boxed warning. Cost and coverage rules differ across all three, so switching between them typically requires a new prior authorization.
